Streetwise Tools & Diagnostics Articles



Marcel Wijma

Probe Biotech's Diverse Subsectors for Undervalued Companies: Van Leeuwenhoeck's Marcel Wijma
Source: Gail Dutton of The Life Sciences Report  (7/1/15)
The life sciences industry is evolving rapidly. Many say it's at the beginning of an explosive growth stage that will see the development and commercialization of novel therapeutics and diagnostics still being imagined in scientific laboratories today. This explosion of innovation also means an explosion of investment opportunity. In this interview with The Life Sciences Report, Marcel Wijma, chief research analyst at Van Leeuwenhoeck Institute, explores some smaller companies working on the industry's forefront. More >


Pooya Hemami

The Big Picture: Edison's Pooya Hemami Looks Beyond Cancer for Biotech Winners
Source: Peter Byrne of The Life Sciences Report  (6/10/15)
Analyst Pooya Hemami of Edison Investment Research casts a wide net when it comes to investment opportunities in the life sciences. You name it, his universe includes it: artificial sweeteners, blood tests, sleep aids, cancer treatments, brain health. In this interview with The Life Sciences Report, Dr. Hemami reflects on the biotech market at midyear, and describes a robust basket of outstanding companies with pipeline treasures. More >


explosion175

Why Your Last Investment Blew Up
Source: Karl Theil, BioPharm Executive  (3/24/15)
"There are tightly designed, highly predictive Phase 2 studies, and then there are Hail Mary studies aimed at moving into pivotal trials, fingers crossed, as quickly as possible. You can't tell where a given program may lie on the spectrum based on headlines. . ." More >


mergeahead175

Pharma Stock Outlook: Let's Make a Deal
Source: Zacks Investment Research  (3/17/15)
"AbbVie's $21B acquisition agreement with Pharmacyclics is one of the biggest deals to be announced in recent times. The deal goes to show that lofty valuations will not deter large companies from pursuing acquisitions to boost their pipelines and product portfolios." More >


Changing of the Guard at FDA: Is Califf the Next Commissioner?
Source: Damian Garde, FierceBiotech   (2/5/15)
"Under Margaret Hamburg's watch, the FDA instituted a slew of programs designed to speed up the review process for new drugs, and 2014 saw the agency approve a 20-year-record 51 novel therapies." More >


biodip175

Buy on the Biotech Dip
Source: Greg Guenthner, The Daily Reckoning  (2/5/15)
"Biotechs are still on the rampage. Feeble market in January? Biotechs don't care. They just kept bulldozing forward. In fact, biotechs were some of the only stocks popping to start the year." More >


Watchlist Analysts Forecast Continued Blue Sky for Biotech Industry
Source: Tracy Salcedo-Chourré of The Life Sciences Report  (1/29/15)
For the last two years the biotech sector has experienced market-beating gains, even taking into account the industry-wide hiccup in early 2014. Can this trend continue? The five analysts who selected names for The Life Sciences Report's 2015 Small-Cap Biotech Watchlist spend their days considering this question; it comes into play with every recommendation they make. The topic came up in various contexts during the Watchlist panel at the 2015 Biotech Showcase: Here are four factors investors should consider as they move into 2015. More >


stethobilfold175

Biotech Watchlist Update: Small-Cap Biotechs Struggle to Rebound
Source: Tracy Salcedo-Chourré of The Life Sciences Report  (11/6/14)
When the biotechnology market hit a speed bump in early 2014, every stock in the sector was jolted. Large-cap biotech and big pharma have largely recovered, but small- and micro-cap companies haven't yet entirely recouped the losses. The performance of Streetwise Reports' Biotechnology Watchlist to date reflects this trend: The portfolio lingered in negative territory after the late-winter punch, and hovers near breakeven as of Nov. 3. To get a handle on the drivers of small-cap stock price volatility, The Life Sciences Report turned to a pair of the analysts who selected companies for the 2014 Watchlist, John McCamant of the Medical Technology Stock Letter and George Zavoico of MLV & Co. In this recap, the two experts offer updates on the companies they selected for the portfolio. More >


merger175

Is Biotech M&A Mojo Here to Stay? Bright Prospects and Rising Firepower Drive Deals
Source: Andrew Forman, EY  (10/23/14)
"Despite modest revenue growth, the industry has provided a total return to shareholders in excess of the performance of most major stock indices in 2014." More >


Anita Dushyanth

Three Biotech Investment Ideas that Disrupt and Diversify: Anita Dushyanth
Source: Peter Byrne of The Life Sciences Report  (9/25/14)
Good management. Promising therapies in the pipeline. Marketed products that bolster the bottom line. Investors crave these bread-and-butter qualities in small-cap biotech and medtech companies. Anita Dushyanth of Zacks Investment Research relies on the staples, but also looks for something special, something that disrupts. In this interview with The Life Sciences Report, Dushyanth describes several small companies that have spiced up their offerings. More >


Steve Brozak

Steve Brozak: Big-Picture Biotech Stocks Rule the Future
Source: George S. Mack of The Life Sciences Report  (9/4/14)
When Steve Brozak performs diligence on biotech stocks, he's always looking for an angle. Brozak, president and managing director at WBB Securities, wants to see how new technology platforms and novel ideas fit into tomorrow's healthcare system, which he believes will be unsustainable without therapies that work more efficiently and hold promise as true disease-modifying agents. In this interview with The Life Sciences Report, Brozak brings eight names to investors' attention. Given time, each holds the potential to be a huge gainer. More >


biodeals175

Recap Analysis: Dealmaking in Life Sciences Remains On Robust Pace
Source: Peter Winter, BioWorld Insight  (8/4/14)
"Recap's data clearly indicate a robust deal environment in the life sciences industry in the first half of this year, with volume reaching 1,337 transactions involving not only biopharmaceutical companies but also medical devices, diagnostics and tools firms." More >


breakout2175

Into Record-Setting Territory: Huge Q2 for Biotech and Pharma M&A
Source: Amy Brown, EP Vantage   (7/9/14)
"The stampede of U.S. companies seeking shelter from the country’s high domestic corporation tax rate has largely driven the deal making. This financial engineering has been widely applauded by the markets but has increasingly been raising the ire of politicians." More >


biobubble1

Bubble? What Bubble? The BioScience Profit Outlook for the Rest of 2014
Source: Ernie Tremblay, Money Morning  (7/2/14)
"Bioscience investors are putting their money into companies making good drugs with solid data that meet critical needs in the real world. They're helping fuel R&D into terrible and terrifying diseases, and they're funding the distribution of those products into a waiting market." More >


purpleflask175

Healthcare Sector Spurred by Population Growth and M&As
Source: Frank Holmes, U.S. Global Investors  (6/27/14)
"The recent trend in healthcare M&As has many benefits, not least of which is the ability to reach a wider range of people who depend on the drugs and treatments the industry delivers." More >


traffic175

The Traffic Jam that Kills Thousands of People Every Day
Source: Juan Enriquez, Tomorrow in Review  (4/22/14)
"But the real question is by not approving drugs in the renal and cardiac unit, did he also kill people by not acting? Are there consequences to not acting? Because sometimes by not acting, by being too careful, by making it too expensive, maybe we're killing more people than regulation is saving." More >


Scott Power

Four Hidden Australian Life Sciences Growth Stocks Revealed: Scott Power
Source: George S. Mack of The Life Sciences Report  (4/17/14)
To find undiscovered stories, investors must venture into unfamiliar territory. In this interview with The Life Sciences Report, we go halfway around the world to speak with Scott Power of Morgans Financial Ltd. about companies under coverage in Australia. Power helps investors get comfortable with the idea of putting money into newfound names, and unveils four strong ideas that could invigorate adventuresome portfolios and investors hungering for excitement. More >


Grant Zeng

Build Biotech Wealth on Solid Platforms: Grant Zeng
Source: Peter Byrne and Tracy Salcedo-Chourré of The Life Sciences Report  (4/17/14)
Potential. That's what every investor is looking for in a biotech investment. Grant Zeng of Zacks Small-Cap Research zeroes in on three primary factors when he looks at whether a particular company has the potential to succeed in the fast-moving life sciences industry. In this interview with The Life Sciences Report, Zeng dissects his process and names 10 companies that have survived his exacting examination. More >


Thomas Braun

Novel Tools for Early Cancer Detection: Verisante Technology Inc.
Source: Daniel Levy of The Life Sciences Report  (4/17/14)
Early detection of cancer has a profound impact on the effectiveness of medical/surgical treatments, as well as on the long-term prognoses of patients. Consequently, new technologies are evolving with the ability to detect cancers in their earliest and most treatable stages. In this interview with The Life Sciences Report, Thomas Braun, president and CEO of Verisante Technology Inc., describes his company's Aura and Core devices, and their utility in early cancer detection. More >


Keith Markey

Don't Miss the Boat on Big Biotech Catalysts: Keith Markey
Source: George S. Mack of The Life Sciences Report  (4/10/14)
Keith Markey, veteran analyst and science director of Griffin Securities, tells us the 2014 pipeline calendar positively glows with important milestones that could ignite portfolios. In this interview with The Life Sciences Report, Markey talks about four powerful biotech names with exciting early- to late-stage development projects, and one medical device and supply company with serious growth potential. Be warned—huge catalysts are on the horizon that investors won't want to miss. More >


Hang On, Folks—It's Going to Be a Bumpy Ride: 2014 Biotech Watchlist Update
Source: Tracy Salcedo-Chourré of The Life Sciences Report  (4/10/14)
stethbillfold8214Biotech stocks sailed into 2014 backed by a favorable wind, but springtime has stymied the sector in confused seas. Companies on The Life Sciences Report's 2014 Biotech Watchlist have hit the doldrums along with the rest, as faithful followers of the portfolio are doubtless aware. But sector analysts defend the general robustness of the life sciences market as a whole. In this Biotech Watchlist update, we bring you the thoughts of two analysts on the recent market turbulence, and offer brief recaps of Watchlist companies' fortunes year to date. More >


mouse175

Putting Money Where the Mouse Is: How Animal Studies Lead Medical Research Down Dead Ends
Source: Richard Harris, NPR  (4/8/14)
"If scientists had been more careful with their initial mouse studies, they would have realized that these drugs were never good candidates and that it made no sense to try them in people." More >


Jason Kolbert

How Did High Flyers Turn into Soul Searchers? Maxim Analyst Jason Kolbert on the Highs and Lows of Biotech Valuations
Source: Editors, Streetwise Reports  (4/2/14)
After soaring more than 56% last year, the NASDAQ Biotechnology Index is down almost 15% in March. In this interview with The Life Sciences Report, Jason Kolbert of the Maxim Group points to increased approval rates and a better economic and regulatory environment as the fundamentals behind a revaluation that has occurred in the sector. Kolbert also reflects on recent concerns about pricing and policy changes that have triggered what he considers a normal, healthy correction in an otherwise robust and intact sector. More >


George Zavoico

Shining a Light on Overlooked and Underfollowed Biotechs: George Zavoico
Source: George S. Mack of The Life Sciences Report  (3/6/14)
Prospecting for hidden biotech gems makes sense, says H.C. Wainwright & Co. Managing Director George Zavoico, who recently joined the firm's healthcare equity research team. The digging can be hard, but the rewards of successful diligence are huge. In this interview with The Life Sciences Report, Zavoico takes readers on a discovery tour that follows clinical trial data to new ideas that could bring windfalls to portfolios down the road. More >


Ben Haynor

Better, Faster, Cheaper—You Can Have All Three in Medtech: Ben Haynor
Source: George S. Mack of The Life Sciences Report  (3/5/14)
Given that medical technology is an easy target for payers looking to cut reimbursements, it's important for investors to find device and diagnostic companies with the greatest efficiencies. Accuracy, speed and economy command a premium multiple because these features ultimately relieve pressure on margins, improve quality and reduce patient risk and institutional liability. In this interview with The Life Sciences Report, Senior Research Analyst Ben Haynor of Feltl & Co. shares his top two medtech names, which he expects will achieve outsized gains this year. He also delivers a couple of bonus names that investors could parlay into a profitable small- and micro-cap portfolio. More >


Showing Results: 26 to 50 of 183 Prev Next

Notable Quotes

"We are initiating coverage on PMN."
– John Vandermosten, Zacks Small-Cap Research
"We are initiating coverage on GSV with a Buy rating."
– Bhakti Pavani, Euro Pacific Canada

Get Our Streetwise Reports Newsletter Free and be the first to know!

A valid email address is required to subscribe